GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

Summary

This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other chemotherapy schedule.

Timeline

Start

2006-01

Primary completion

2010-12

Completion

2010-12

Publications

• Results Nabhan C, Meyer A, Tolzien K, Bitran JD, Lestingi TM. A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy. Avicenna J Med. 2011 Jul;1(1):12-7. doi: 10.4103/2231-0770.83718.

Drugs

Indications